全文获取类型
收费全文 | 26989篇 |
免费 | 1997篇 |
国内免费 | 66篇 |
专业分类
耳鼻咽喉 | 246篇 |
儿科学 | 798篇 |
妇产科学 | 553篇 |
基础医学 | 3310篇 |
口腔科学 | 404篇 |
临床医学 | 2667篇 |
内科学 | 5332篇 |
皮肤病学 | 721篇 |
神经病学 | 2375篇 |
特种医学 | 1045篇 |
外国民族医学 | 1篇 |
外科学 | 4118篇 |
综合类 | 419篇 |
一般理论 | 60篇 |
预防医学 | 2303篇 |
眼科学 | 860篇 |
药学 | 1817篇 |
中国医学 | 31篇 |
肿瘤学 | 1992篇 |
出版年
2022年 | 172篇 |
2021年 | 403篇 |
2020年 | 260篇 |
2019年 | 391篇 |
2018年 | 477篇 |
2017年 | 411篇 |
2016年 | 435篇 |
2015年 | 491篇 |
2014年 | 768篇 |
2013年 | 1088篇 |
2012年 | 1623篇 |
2011年 | 1672篇 |
2010年 | 954篇 |
2009年 | 848篇 |
2008年 | 1584篇 |
2007年 | 1621篇 |
2006年 | 1599篇 |
2005年 | 1652篇 |
2004年 | 1609篇 |
2003年 | 1505篇 |
2002年 | 1481篇 |
2001年 | 409篇 |
2000年 | 318篇 |
1999年 | 352篇 |
1998年 | 345篇 |
1997年 | 317篇 |
1996年 | 290篇 |
1995年 | 272篇 |
1994年 | 238篇 |
1993年 | 236篇 |
1992年 | 281篇 |
1991年 | 251篇 |
1990年 | 229篇 |
1989年 | 230篇 |
1988年 | 204篇 |
1987年 | 193篇 |
1986年 | 188篇 |
1985年 | 224篇 |
1984年 | 215篇 |
1983年 | 217篇 |
1982年 | 248篇 |
1981年 | 256篇 |
1980年 | 212篇 |
1979年 | 168篇 |
1978年 | 178篇 |
1977年 | 169篇 |
1976年 | 115篇 |
1975年 | 132篇 |
1974年 | 143篇 |
1973年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
11.
This paper introduces the ‘foot function’ approach used by podiatrists in the treatment of lower limb musculoskeletal dysfunction. The aim is to demonstrate how podiatric theory has evolved its own perspective of mechanisms relating to normal and abnormal locomotion. Three individual podiatric paradigms are discussed, and a further theory allowing a working simplification of theory is introduced. Finally, an example of gait abnormality is discussed in relation to podiatric and physiotherapy perspectives.An insight into podiatric theory should enable therapists working within this field to develop a more holistic and multidisciplinary approach. It is the view of the authors that a closer working relationship between physiotherapists and podiatrists with an interest in movement dysfunction provides a better quality service for appropriate patients. 相似文献
12.
Christine E. Marx William T. Trost Lawrence J. Shampine Robert D. Stevens Christine M. Hulette David C. Steffens John F. Ervin Marian I. Butterfield Daniel G. Blazer Mark W. Massing Jeffrey A. Lieberman 《Neuropsychopharmacology》2006,60(12):1287-1294
BACKGROUND: Few data are currently available investigating neurosteroids (NS) in Alzheimer's disease (AD). The NS allopregnanolone may be decreased in serum and plasma in patients with AD, but it is unclear if allopregnanolone is also reduced in brain. Because a number of NS exhibit neuroprotective effects and impact cognitive performance in rodent models, these molecules may be relevant to the pathophysiology of neurodegenerative disorders. We therefore investigated prefrontal cortex (PFC) NS levels in AD. METHODS: Neurosteroid levels (allopregnanolone, pregnenolone, dehydroepiandrosterone [DHEA]) were determined in postmortem PFC in 14 male subjects with AD and 15 cognitively intact male control subjects by gas chromatography/mass spectrometry preceded by high-performance liquid chromatography purification. RESULTS: Subjects with AD exhibit significant reductions in allopregnanolone compared with cognitively intact control subjects (median levels = 2.50 ng/g vs. 5.59 ng/g, respectively; p = .02). Allopregnanolone levels are inversely correlated with neuropathological disease stage (Braak), r = -.49, p = .007. Median DHEA levels are elevated in subjects with AD (p = .01). CONCLUSIONS: Subjects with AD demonstrate significant reductions in PFC allopregnanolone levels, a finding that may be relevant to neuropathological disease stage severity. Neurosteroids may have utility as candidate biomarkers in AD. 相似文献
13.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献
14.
15.
Juvenile hypocalcemia provokes persistent electroencephalographic change in renally compromised rats
J J Lipman D L White P L Lawrence P E Teschan 《Journal of the American College of Nutrition》1988,7(6):453-460
In view of the putative involvement of calcium in uremic encephalopathy and the critical importance of this element in juvenile development, we examined the effect of temporary restriction of dietary calcium intake on serum chemistry and the quantitative electroencephalogram (Q.EEG) in unilaterally 3/4 nephrectomized juvenile male Sprague-Dawley rats. Animals were renally infarcted at 22-26 days of age (50-74 g) and placed on one of two isocaloric dietary regimens: powdered normal rat diet (ND, n = 25) or low calcium diet (LCD, n = 8) for 30 days. At this time, ND animals showed normal serum chemistries, whereas LCD rats were hypocalcemic and azotemic with significantly elevated blood urea nitrogen (BUN) and serum creatinine concentrations and reduced renal creatinine clearance values. All animals thereafter received ND for 25-34 further days, during which time chronic Q.EEG electrodes were implanted. At the end of the common ND feeding period, serum chemistry values were equal and normal in both groups. The average theta/alpha ratio (TAR) of the overnight Q.EEG was assessed for 3 days. We found that the TAR of previously LCD animals was significantly elevated compared with ND rats. This indicates an encephalopathic slowing of the background rhythm of these animals. We conclude that, following restoration of a transient uremic and hypocalcemic episode induced by LCD feeding, the Q.EEG background frequency of juvenile renally impaired rats was abnormally slow after 30 days of ND feeding. 相似文献
16.
Lori Dorfman Lawrence Wallack Katie Woodruff 《Health education & behavior》2005,32(3):320-36; discussion 355-62
Framing battles in public health illustrate the tension in our society between individual freedom and collective responsibility. This article describes how two frames, market justice and social justice, first articulated in a public health context by Dan Beauchamp, influence public dialogue on the health consequences of corporate practices. The authors argue that public health advocates must articulate the social justice values motivating the changes they seek in specific policy battles that will be debated in the context of news coverage. The authors conclude with lessons for health education practitioners who need to frame public health issues in contentious and controversial policy contexts. Specific lessons include the importance of understanding the existing values and beliefs motivating the public health change being sought, the benefits of articulating core messages that correspond to shared values, and the necessity of developing media skills to compete effectively with adversaries in public debate. 相似文献
17.
18.
19.
20.